FY2025 Earnings Estimate for PRQR Issued By Chardan Capital

ProQR Therapeutics (NASDAQ:PRQR) – Chardan Capital raised their FY2025 earnings per share estimates for ProQR Therapeutics in a report issued on Monday, March 24th. Chardan Capital analyst K. Nakae now anticipates that the biopharmaceutical company will earn ($0.33) per share for the year, up from their previous forecast of ($0.34). Chardan Capital currently has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share.

PRQR has been the subject of a number of other reports. StockNews.com lowered shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. Oppenheimer began coverage on ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 target price on the stock. Citigroup upgraded ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Monday, March 10th. HC Wainwright upped their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, March 14th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ProQR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $9.50.

ProQR Therapeutics Stock Down 5.6 %

Shares of NASDAQ PRQR opened at $1.52 on Thursday. The company has a market cap of $159.92 million, a P/E ratio of -4.75 and a beta of 0.24. ProQR Therapeutics has a 52 week low of $1.50 and a 52 week high of $4.62. The business has a 50-day simple moving average of $2.11 and a two-hundred day simple moving average of $2.60.

Institutional Trading of ProQR Therapeutics

Hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new position in ProQR Therapeutics during the fourth quarter valued at approximately $30,000. Invesco Ltd. bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at $32,000. Alpine Global Management LLC purchased a new position in ProQR Therapeutics in the 4th quarter worth $39,000. Two Sigma Securities LLC bought a new stake in ProQR Therapeutics in the fourth quarter worth $40,000. Finally, ADAR1 Capital Management LLC purchased a new stake in ProQR Therapeutics during the fourth quarter valued at about $54,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).